Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

NCT05472623 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no participants enrolled across sites

Conditions

Resectable Non-Small Cell Lung Cancer

Interventions

DRUG: Adagrasib
COMBINATION_PRODUCT: Adagrasib/Nivolumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]